For updated information about JADPRO Live 2021, please visit JADPROLive.com

CURRENT ISSUE Current Issue Cover
VOL 12 NO 3 • APR 2021
IN THIS ISSUE

JADPRO Live Virtual 2020: Learning Today, Leading Tomorrow

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN

Advanced Practitioner Leadership in Times of Crisis

Presented by Gabrielle Zecha,(1) PA-C, MHA, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, David Johnson,(3) PA-C, and Sara Toth,(4) RN, APRN, FNP-C, AOCNP®, AGN-BC

Words Matter: Use of Respectful Language in Oncology

Presented by Laura J. Zitella,(1) MS, RN, ACNP-BC, AOCN®, and Tatiana M. Prowell,(2) MD


 
Section Seperator

TODAY'S NEWS

Mutational Profile of Acral Nevi May Dif...

Melanocytic nevi are nonmalignant growths that ari...

Abemaciclib-Associated Adverse Events Sa...

Treatment with abemaciclib, an orally available in...

FDA Pipeline Priority Reviews of Treatme...

Recently, the U.S. Food and Drug Administration (F...

First-Line Single-Agent Carboplatin vs C...

In a phase II trial reported in JAMA Oncology, Fal...

Antiviral T Cells for BK Virus–Associate...

A phase II trial has found found that BK virus (BK...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

https://www.advancedpractitioner.com/issues/volume-11,-number-6-(aug-2020)/asco20-virtual-scientific-program-takeaways-for-the-advanced-practitioner.aspx

CAR T-cell therapy is rapidly emerging as a promising treatment for many hematologic malignancies...

Rare Myeloproliferative Neoplasm w/CSF3R

Cases of chronic neutrophilic leukemia (CNL) are extremely rare and easily missed...

Management of Carcinoid Syndrome

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors...

APs: Collaborators in Radiation Oncology

Advanced practitioners, including physician assistants and nurse practitioners, are medical professionals with...

Axicabtagene Ciloleucel: CAR T-Cell Therapy

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

Gemcitabine/Eribulin in Cisplatin-Inelig...

In the final analysis from a phase II California C...

Deintensified Chemoradiotherapy for HPV-...

In a phase II trial reported in the Journal of Cli...

USPSTF Recommendation on Risk Assessment...

As reported in JAMA, the U.S. Preventive Services ...

Incidence of HPV-Associated Head and Nec...

In a study by Mahal et al published in Cancer Epid...

Racial Reporting and Representation in O...

New research published by Loree et al in JAMA Onco...

More Highlights More Highlights
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
 
 
Designed by Harborside
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.